bemiparin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
heparin derivatives including low molecular mass heparins	4840	9041-08-1

Description:

Molecule	Description
Synonyms: tinzaparin ardeparin sodium dalteparin sodium tinzaparin sodium bemiparin bemiparin sodium	A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed) Molecular weight: Formula: None CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

tinzaparin
ardeparin sodium
dalteparin sodium
tinzaparin sodium
bemiparin
bemiparin sodium

A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Molecular weight:
Formula: None
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
3.50	TU	P
2.50	TU	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 22, 1994	FDA	PFIZER INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary embolism	219.81	12.72	259	21057	108326	46556420
Hepatocellular injury	124.22	12.72	105	21211	29417	46635329
Toxic epidermal necrolysis	107.89	12.72	86	21230	22192	46642554
Drug ineffective	103.38	12.72	95	21221	677743	45987003
Acute kidney injury	96.91	12.72	281	21035	235574	46429172
General physical health deterioration	95.04	12.72	181	21135	115588	46549158
Heparin-induced thrombocytopenia	88.57	12.72	42	21274	4267	46660479
Thrombocytopenia	88.42	12.72	185	21131	126396	46538350
Deep vein thrombosis	74.60	12.72	132	21184	79641	46585105
Rheumatoid arthritis	73.61	12.72	11	21305	240204	46424542
Neutropenic sepsis	62.72	12.72	49	21267	12275	46652471
Cholestasis	59.04	12.72	67	21249	26826	46637920
Arthralgia	55.45	12.72	51	21265	364552	46300194
Product dose omission issue	53.28	12.72	7	21309	168513	46496233
Blood creatine increased	51.95	12.72	30	21286	4560	46660186
Anaemia	47.15	12.72	236	21080	255543	46409203
Neutropenia	45.23	12.72	156	21160	143048	46521698
Vessel puncture site bruise	44.68	12.72	13	21303	328	46664418
Rash maculo-papular	44.27	12.72	59	21257	27815	46636931
Malignant neoplasm progression	44.22	12.72	94	21222	64832	46599914
Agranulocytosis	43.23	12.72	52	21264	22133	46642613
Melaena	42.91	12.72	58	21258	27714	46637032
Arteriovenous fistula occlusion	40.72	12.72	12	21304	317	46664429
Venous pressure jugular decreased	40.68	12.72	8	21308	32	46664714
Febrile neutropenia	39.93	12.72	114	21202	94513	46570233
Blue toe syndrome	39.82	12.72	12	21304	343	46664403
Ovarian hyperstimulation syndrome	39.18	12.72	22	21294	3170	46661576
Pituitary tumour	39.14	12.72	15	21301	900	46663846
Adrenal suppression	38.57	12.72	15	21301	936	46663810
Drug intolerance	38.18	12.72	10	21306	147039	46517707
Hypothalamo-pituitary disorder	35.86	12.72	13	21303	667	46664079
Drug reaction with eosinophilia and systemic symptoms	35.82	12.72	55	21261	29493	46635253
Thrombosis	35.69	12.72	79	21237	55990	46608756
Gamma-glutamyltransferase increased	35.59	12.72	57	21259	31683	46633063
Headache	35.35	12.72	107	21209	478245	46186501
Haemoglobin decreased	35.21	12.72	134	21182	128815	46535931
Drug hypersensitivity	34.82	12.72	36	21280	243789	46420957
Perforation	34.56	12.72	14	21302	973	46663773
Pancytopenia	34.46	12.72	101	21215	84957	46579789
Blood loss anaemia	33.05	12.72	29	21287	8528	46656218
Depression	32.00	12.72	19	21297	170085	46494661
Abdominal wall haemorrhage	30.59	12.72	8	21308	134	46664612
Haematoma	30.09	12.72	53	21263	31819	46632927
Sinusitis	29.78	12.72	11	21305	129757	46534989
Feeling abnormal	29.73	12.72	10	21306	125050	46539696
Pneumothorax traumatic	29.64	12.72	8	21308	152	46664594
Cerebral haemorrhage	27.85	12.72	48	21268	28323	46636423
Abdominal wall haematoma	27.83	12.72	17	21299	2864	46661882
Dermatitis exfoliative	27.52	12.72	22	21294	5694	46659052
Blood creatinine increased	27.46	12.72	87	21229	76316	46588430
Hyperkalaemia	27.39	12.72	67	21249	50642	46614104
Jaundice	27.28	12.72	48	21268	28797	46635949
Cardiomyopathy acute	27.20	12.72	8	21308	210	46664536
Pyrexia	26.94	12.72	260	21056	348542	46316204
Biliary sepsis	26.77	12.72	10	21306	559	46664187
Gastric antral vascular ectasia	26.55	12.72	10	21306	572	46664174
Catheter site thrombosis	26.40	12.72	7	21309	124	46664622
Psychiatric decompensation	26.35	12.72	12	21304	1111	46663635
Activated partial thromboplastin time prolonged	25.91	12.72	23	21293	6866	46657880
Intra-abdominal haemorrhage	25.76	12.72	15	21301	2315	46662431
Hyperthyroidism	25.39	12.72	29	21287	11682	46653064
Bronchopulmonary dysplasia	25.36	12.72	8	21308	267	46664479
Cardiac failure	25.12	12.72	87	21229	79861	46584885
Haemorrhagic erosive gastritis	25.00	12.72	8	21308	280	46664466
Bone marrow eosinophilic leukocyte count increased	24.86	12.72	5	21311	23	46664723
Therapeutic product effect decreased	24.77	12.72	4	21312	82597	46582149
Exposure during pregnancy	24.40	12.72	106	21210	108106	46556640
Allergic hepatitis	23.89	12.72	5	21311	29	46664717
Drug interaction	23.52	12.72	166	21150	202928	46461818
Arthropathy	23.47	12.72	5	21311	84695	46580051
Muscle haemorrhage	23.30	12.72	16	21300	3288	46661458
Ascites	22.66	12.72	51	21265	36533	46628213
Phlebitis	22.43	12.72	20	21296	6006	46658740
Premature baby	22.35	12.72	34	21282	18078	46646668
Gastrointestinal haemorrhage	21.59	12.72	81	21235	77292	46587454
Femoral neck fracture	20.93	12.72	22	21294	8081	46656665
Pleural effusion	20.83	12.72	84	21232	82868	46581878
Abdominal discomfort	20.79	12.72	23	21293	151142	46513604
Hepatitis cholestatic	20.68	12.72	20	21296	6657	46658089
Cardiac failure congestive	20.67	12.72	8	21308	91742	46573004
Pain	20.37	12.72	131	21185	476817	46187929
Caesarean section	20.25	12.72	31	21285	16572	46648174
Granulomatous liver disease	19.93	12.72	9	21307	817	46663929
Neoplasm progression	19.76	12.72	40	21276	26643	46638103
Renal tubular acidosis	19.67	12.72	11	21305	1572	46663174
Intra-abdominal haematoma	19.37	12.72	11	21305	1620	46663126
Cholestatic liver injury	19.34	12.72	12	21304	2078	46662668
Foetal growth restriction	19.09	12.72	19	21297	6548	46658198
Joint swelling	19.00	12.72	29	21287	166044	46498702
Haematoma muscle	18.92	12.72	8	21308	620	46664126
Retroperitoneal haemorrhage	18.73	12.72	13	21303	2717	46662029
Diarrhoea haemorrhagic	18.71	12.72	20	21296	7489	46657257
Sepsis	18.65	12.72	116	21200	135898	46528848
Musculoskeletal stiffness	18.34	12.72	11	21305	97982	46566764
Fatigue	18.25	12.72	184	21132	608513	46056233
Limbal swelling	18.11	12.72	4	21312	31	46664715
Electrolyte imbalance	18.04	12.72	30	21286	17196	46647550
Anaemia folate deficiency	17.77	12.72	6	21310	249	46664497
Multiple organ dysfunction syndrome	17.77	12.72	58	21258	51652	46613094
Epistaxis	17.67	12.72	67	21249	64238	46600508
Gastric ulcer	17.67	12.72	34	21282	21829	46642917
Cerebral infarction	17.26	12.72	35	21281	23331	46641415
Alanine aminotransferase increased	17.22	12.72	83	21233	88368	46576378
Lordosis	17.04	12.72	6	21310	283	46664463
Protein C decreased	16.85	12.72	4	21312	44	46664702
Respiratory disorder	16.84	12.72	38	21278	27262	46637484
Treatment failure	16.66	12.72	11	21305	93076	46571670
Haemolysis	16.64	12.72	17	21299	6042	46658704
Acute generalised exanthematous pustulosis	16.63	12.72	21	21295	9384	46655362
Faecaloma	16.47	12.72	19	21297	7733	46657013
Pneumobilia	16.20	12.72	5	21311	155	46664591
Asthma	16.14	12.72	11	21305	91531	46573215
Maternal drugs affecting foetus	16.10	12.72	16	21300	5502	46659244
Gastrointestinal tract adenoma	16.08	12.72	6	21310	334	46664412
Varices oesophageal	16.08	12.72	12	21304	2807	46661939
Constipation	16.07	12.72	135	21181	173962	46490784
Blood alkaline phosphatase increased	15.99	12.72	47	21269	39562	46625184
Visual acuity reduced transiently	15.96	12.72	5	21311	163	46664583
Protein S decreased	15.96	12.72	4	21312	56	46664690
Hyperlipasaemia	15.92	12.72	7	21309	597	46664149
Toxicity to various agents	15.84	12.72	47	21269	211719	46453027
Infantile haemangioma	15.83	12.72	4	21312	58	46664688
Therapeutic product effect incomplete	15.74	12.72	8	21308	78145	46586601
Intracranial pressure increased	15.70	12.72	14	21302	4206	46660540
Cerebellar haematoma	15.53	12.72	6	21310	368	46664378
Mucosal inflammation	15.50	12.72	46	21270	38930	46625816
Chemotherapeutic drug level increased	15.49	12.72	5	21311	180	46664566
Needle issue	15.42	12.72	16	21300	5788	46658958
Acidosis	15.26	12.72	22	21294	11152	46653594
Gait disturbance	15.10	12.72	27	21289	145236	46519510
Thrombophlebitis	15.09	12.72	14	21302	4423	46660323
Cardiac hypertrophy	14.95	12.72	8	21308	1049	46663697
Cholecystitis	14.89	12.72	25	21291	14441	46650305
Persecutory delusion	14.85	12.72	11	21305	2544	46662202
International normalised ratio increased	14.70	12.72	51	21265	46832	46617914
Haemoptysis	14.56	12.72	35	21281	26154	46638592
Embolism	14.34	12.72	17	21299	7121	46657625
Subcutaneous haematoma	14.33	12.72	9	21307	1592	46663154
Abdominal pain	14.20	12.72	164	21152	229867	46434879
Hyperhidrosis	14.12	12.72	12	21304	89296	46575450
Vena cava thrombosis	14.07	12.72	10	21306	2169	46662577
Chondrodystrophy	14.06	12.72	4	21312	93	46664653
Haemangioma congenital	13.96	12.72	6	21310	484	46664262
Stevens-Johnson syndrome	13.89	12.72	32	21284	23265	46641481
Foetal growth abnormality	13.85	12.72	3	21313	21	46664725
Bone marrow oedema	13.71	12.72	7	21309	834	46663912
Vascular occlusion	13.61	12.72	7	21309	846	46663900
Engraftment syndrome	13.37	12.72	5	21311	280	46664466
Red cell distribution width increased	13.31	12.72	17	21299	7687	46657059
Eosinophilia	13.27	12.72	28	21288	19189	46645557
Leukopenia	13.20	12.72	64	21252	68279	46596467
Post procedural haematoma	13.12	12.72	8	21308	1343	46663403
Injection site erythema	13.04	12.72	9	21307	74418	46590328
Injection site pain	12.95	12.72	18	21298	107134	46557612
Alopecia	12.91	12.72	35	21281	162379	46502367
Application site haemorrhage	12.88	12.72	7	21309	947	46663799
Loss of personal independence in daily activities	12.86	12.72	5	21311	57178	46607568
Alveolitis	12.80	12.72	10	21306	2503	46662243
Erythema	12.77	12.72	110	21206	142710	46522036
Osteochondrosis	12.77	12.72	7	21309	963	46663783

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary embolism	116.43	12.88	189	18493	77946	29855850
Hepatocellular injury	85.62	12.88	92	18590	25379	29908417
Drug ineffective	75.85	12.88	61	18621	340326	29593470
General physical health deterioration	72.52	12.88	179	18503	99765	29834031
Thrombocytopenia	64.66	12.88	210	18472	136834	29796962
Acute kidney injury	62.88	12.88	336	18346	273506	29660290
Heparin-induced thrombocytopenia	57.59	12.88	38	18644	5345	29928451
Lymph node calcification	51.67	12.88	14	18668	194	29933602
Appendicolith	51.63	12.88	20	18662	899	29932897
Toxic epidermal necrolysis	48.69	12.88	58	18624	17882	29915914
Neutropenia	47.66	12.88	182	18500	128358	29805438
Toxicity to various agents	37.79	12.88	33	18649	177150	29756646
Pulmonary sarcoidosis	37.41	12.88	14	18668	572	29933224
Deep vein thrombosis	37.27	12.88	102	18580	60399	29873397
Drug abuse	37.05	12.88	4	18678	82068	29851728
Sepsis	36.47	12.88	184	18498	146211	29787585
Aplasia	34.92	12.88	25	18657	4012	29929784
Haemorrhage	31.74	12.88	81	18601	45998	29887798
Mucosal inflammation	31.52	12.88	63	18619	30431	29903365
Bronchial disorder	31.39	12.88	14	18668	900	29932896
Suspected product quality issue	30.87	12.88	9	18673	165	29933631
Muscle haemorrhage	29.91	12.88	22	18660	3681	29930115
Hepatic haematoma	28.77	12.88	11	18671	477	29933319
Peritoneal haematoma	28.59	12.88	7	18675	63	29933733
Haematemesis	28.13	12.88	55	18627	26148	29907648
Bronchial obstruction	27.79	12.88	15	18667	1461	29932335
Pancytopenia	27.13	12.88	115	18567	84937	29848859
Chondrocalcinosis	27.01	12.88	9	18673	260	29933536
Floppy infant	26.61	12.88	7	18675	86	29933710
Death	26.42	12.88	124	18558	357159	29576637
Septic shock	25.98	12.88	93	18589	63514	29870282
Hyperkalaemia	25.68	12.88	95	18587	65915	29867881
Compartment syndrome	25.01	12.88	17	18665	2510	29931286
Genitalia external ambiguous	23.92	12.88	8	18674	234	29933562
Lung cancer metastatic	22.66	12.88	16	18666	2512	29931284
Febrile neutropenia	22.38	12.88	128	18554	106565	29827231
Rash maculo-papular	22.18	12.88	49	18633	25369	29908427
Congenital bladder anomaly	22.08	12.88	8	18674	298	29933498
Haematoma	21.84	12.88	47	18635	23906	29909890
Abdominal pain	21.78	12.88	152	18530	135502	29798294
Mucosal disorder	21.62	12.88	13	18669	1554	29932242
Klebsiella infection	21.60	12.88	24	18658	6863	29926933
Embolism	21.25	12.88	24	18658	6985	29926811
Respiratory tract infection	21.01	12.88	36	18646	15470	29918326
Product dose omission issue	20.83	12.88	16	18666	91615	29842181
Cholestasis	20.54	12.88	47	18635	24903	29908893
Thrombocytosis	20.46	12.88	17	18665	3396	29930400
Foetal hypokinesia	20.45	12.88	8	18674	369	29933427
Haemorrhagic disorder	20.37	12.88	9	18673	566	29933230
Malignant neoplasm progression	20.21	12.88	94	18588	72193	29861603
Full blood count abnormal	20.21	12.88	11	18671	1089	29932707
Hypokalaemia	20.16	12.88	73	18609	50119	29883677
Cardiac failure congestive	20.14	12.88	14	18668	84393	29849403
Coagulation factor VII level decreased	20.09	12.88	6	18676	120	29933676
Product communication issue	19.95	12.88	5	18677	50	29933746
Respiratory disorder neonatal	19.42	12.88	11	18671	1177	29932619
Neonatal respiratory depression	19.38	12.88	8	18674	425	29933371
Pulmonary artery thrombosis	19.18	12.88	9	18673	651	29933145
Prothrombin time shortened	19.16	12.88	12	18670	1543	29932253
Depression	19.06	12.88	17	18665	90420	29843376
Haemolytic anaemia	18.79	12.88	27	18655	9983	29923813
Dizziness	18.60	12.88	61	18621	194848	29738948
Appendicitis	18.56	12.88	21	18661	6123	29927673
Reading disorder	18.39	12.88	7	18675	300	29933496
Jaundice cholestatic	18.09	12.88	18	18664	4533	29929263
Hypertrophic osteoarthropathy	17.50	12.88	5	18677	85	29933711
Butterfly rash	17.08	12.88	5	18677	93	29933703
Wrong strength	16.60	12.88	5	18677	103	29933693
Eosinophil percentage decreased	16.42	12.88	5	18677	107	29933689
Cardiac flutter	16.24	12.88	11	18671	1615	29932181
Miosis	16.12	12.88	22	18660	7754	29926042
Hepatitis cholestatic	15.91	12.88	22	18660	7850	29925946
Drug hypersensitivity	15.52	12.88	12	18670	68507	29865289
Therapeutic product effect prolonged	15.27	12.88	6	18676	280	29933516
Cardiogenic shock	15.27	12.88	33	18649	16828	29916968
Abdominal sepsis	15.19	12.88	9	18673	1048	29932748
Leukopenia	14.94	12.88	72	18610	56087	29877709
Large intestine perforation	14.90	12.88	21	18661	7630	29926166
Insomnia	14.84	12.88	22	18660	93314	29840482
Gamma-glutamyltransferase increased	14.71	12.88	46	18636	29304	29904492
Lung disorder	14.57	12.88	48	18634	31421	29902375
Lymphopenia	14.57	12.88	28	18654	13135	29920661
Agranulocytosis	14.51	12.88	38	18644	21904	29911892
Anxiety	14.47	12.88	21	18661	89850	29843946
Engraftment syndrome	14.40	12.88	8	18674	825	29932971
Portal vein thrombosis	14.33	12.88	14	18668	3450	29930346
Cerebral haemorrhage	14.20	12.88	49	18633	32838	29900958
Pyrexia	14.19	12.88	260	18422	294229	29639567
Myositis	13.93	12.88	24	18658	10353	29923443
Metastatic malignant melanoma	13.86	12.88	11	18671	2059	29931737
Penile necrosis	13.84	12.88	4	18678	71	29933725
Neoplasm progression	13.79	12.88	33	18649	17990	29915806
Soft tissue sarcoma	13.69	12.88	4	18678	74	29933722
Phlebitis	13.32	12.88	14	18668	3761	29930035
Bicytopenia	13.18	12.88	10	18672	1752	29932044
IIIrd nerve disorder	13.08	12.88	4	18678	87	29933709
Gastrointestinal stoma output increased	13.04	12.88	3	18679	20	29933776
Foetal exposure during delivery	13.04	12.88	4	18678	88	29933708
Blood pressure diastolic increased	13.03	12.88	12	18670	2746	29931050
Bladder tamponade	12.90	12.88	6	18676	425	29933371

Pharmacologic Action:

Source	Code	Description
ATC	B01AB10	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group
ATC	B01AB12	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group
FDA CS	M0010191	Heparin, Low-Molecular-Weight
FDA EPC	N0000175586	Low Molecular Weight Heparin
MeSH PA	D000925	Anticoagulants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents
CHEBI has role	CHEBI:50249	anticoagulante

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Pulmonary embolism	indication	59282003	DOID:9477
Deep venous thrombosis	indication	128053003

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10,000IU/0.4ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	DISCN	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
10,000IU/ML (10,000IU/ML)	FRAGMIN	PFIZER	N020287	Jan. 30, 1998	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
12,500IU/0.5ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
15,000IU/0.6ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
18,000IU/0.72ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
2,500IU/0.2ML (12,500IU/ML)	FRAGMIN	PFIZER	N020287	Dec. 22, 1994	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
5,000IU/0.2ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	March 18, 1996	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
7,500 IU/0.75ML	FRAGMIN	PFIZER	N020287	April 4, 2002	DISCN	INJECTABLE	INJECTION	May 16, 2022	NEW PATIENT POPULATION
7,500IU/0.3ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	April 4, 2002	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
95,000IU/3.8ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	April 4, 2002	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
95,000IU/9.5ML (10,000IU/ML)	FRAGMIN	PFIZER	N020287	April 4, 2002	DISCN	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION

Bioactivity Summary:

None

External reference:

ID	Source
N3927D01PB	UNII
9005-49-6	SECONDARY_CAS_RN
4020894	VANDF
4021054	VANDF
4021237	VANDF
4024199	VANDF
C0297268	UMLSCUI
CHEBI:28304	CHEBI
CHEMBL1201448	ChEMBL_ID
CHEMBL3707365	ChEMBL_ID
CHEMBL2108806	ChEMBL_ID
CHEMBL1201460	ChEMBL_ID
DB09258	DRUGBANK_ID
CHEMBL1201414	ChEMBL_ID
6985	INN_ID
7501	INN_ID
D017985	MESH_DESCRIPTOR_UI
D000078222	MESH_DESCRIPTOR_UI
C093450	MESH_SUPPLEMENTAL_RECORD_UI
C411345	MESH_SUPPLEMENTAL_RECORD_UI
772	PUBCHEM_CID
5688	INN_ID
6764	INN_ID
DB06822	DRUGBANK_ID
6846	IUPHAR_LIGAND_ID
104466	RXNORM
15471	MMSL
4531	MMSL
d04659	MMSL
005078	NDDF
007911	NDDF
008338	NDDF
108987000	SNOMEDCT_US
108990006	SNOMEDCT_US
350469004	SNOMEDCT_US
395908006	SNOMEDCT_US
410964003	SNOMEDCT_US
410965002	SNOMEDCT_US
410967005	SNOMEDCT_US
412608008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0195	INJECTION	2500 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0196	INJECTION	5000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0206	INJECTION	7500 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0217	INJECTION	10000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0220	INJECTION	12500 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0223	INJECTION	15000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0228	INJECTION	18000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0232	INJECTION	25000 [iU]	SUBCUTANEOUS	NDA	28 sections